ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO198

Renal IgG Heavy Chain (AH) Amyloidosis as Monoclonal Gammopathy of Renal Significance: From Accurate Diagnosis to Adequate Treatment

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Pascoal, Felipe, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Machado, Enéias Silva, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Vieira, Ana Teresa Pereira, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Cavalcante, Livia Barreira, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Jorge, Lectícia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Noronha, Irene L., Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Yu, Luis, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil

Group or Team Name

  • Division of Nephrology, University of São Paulo.

Monoclonal Gammopathy of Renal Significance (MGRS) is a B or plasma-cell clonal disorder that does not meet the criteria for cancer but produces a monoclonal immunoglobulin that leads to kidney injury. It can rarely manifest as AH amyloidosis, in which highly ordered heavy-chain fibrils deposit in the kidneys. We report a case in which a patient with MGRS was diagnosed and treated for renal AH Amyloidosis.

Case Description

A 77-year-old patient was referred to our Nephrology Clinic due to chronic kidney disease (1.4mg/dL baseline creatinine), proteinuria (2.2g/24h), monoclonal gamma spike (0.75g/dL), hypertension and feet paresthesia. Bone marrow biopsy showed 6% plasmocyte clonal proliferation. Eletrocardiogram, echocardiogram, myocardial scintigraphy and bedside kidney ultrasound were unremarkable. Further workup showed 8.7g/dL hemoglobin, 1.28mmol/L ionized calcium, rare eritrocytes and 2+ protein on urinalysis, 6.3 Kappa-to-Lambda ratio and 1058 mg/dL IgG. Renal biopsy was performed for suspected MGRS with glomerular involvement (images attached). AH Amyloidosis was diagnosed and CyBorD chemotherapy started. After 4 sessions, creatinine and blood urea nitrogen levels improved from 2.2mg/dL and 60.2mg/dL to 1.58mg/dL and 30mg/dL respectively. Proteinuria reached 0.86g/24h.


This is a case of rare renal AH Amyloidosis diagnosed in a patient with hypertension, subnephrotic proteinuria and isolated kidney injury, which differs from the typical hypotension, nephrotic-range pronteinuria and multi-organ involvement seen in AL Amyloidosis. Since elevated serum free light-chain levels might be seen on both conditions, renal biopsy is vital for precise diagnosis and fibril deposit distinction. As new therapies are surging for MGRS and Amyloidosis, there is a need for prompt suspicion and accurate diagnosis, which can improve renal outcomes, mitigate disease burden and prevent overt malignancy such as multiple myeloma.

Kidney Biopsy